9 Meters Biopharma, Inc. · OTC:NMTRQ
9 Meters Biopharma — Merger or Acquisition (July 2021)
10 slides from 9 Meters Biopharma's merger presentation, Jul 19, 2021
Slide 1: 9 Meters – Lobesity Asset Purchase Acquisition
9 Meters – Lobesity Asset Purchase Acquisition July 19, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements based upon the Company's current expectations. Forward- looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements
Slide 3: Lobesity Company Overview
Lobesity Company Overview • Privately-held company based in Cleveland, OH (Lead investor is Metro Health System) • Founded in 2015 by researchers Michael Wolfe, MD (inventor of Pepcid Complete® and former Chair of the Advisory Board for GI Drugs at FDA) and Michael Boylan, PhD (recognized expert in
Slide 4: Transacted Key Deal Terms
Transacted Key Deal Terms 4 9 Meters and Lobesity have agreed to an asset purchase agreement, pursuant to which 9 Meters will acquire NM-136 (formerly LOB-0136), related analogues, and all related intellectual property and other related assets of Lobesity for: • A combination of cash and equity cons
Slide 5: Lobesity and GIP Monoclonal Antibody
▪ Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid hormone made in K-cells localized to the proximal gut, and it is secreted after eating food containing glucose and fat ▪ Although originally named asan acid blocker, the principal property of GIPis the stimulation of insulin release
Slide 6: NM-136 Complements and Adds Potential Strategic Optionality to 9 Meters Pipeline
NM-136 Complements and Adds Potential Strategic Optionality to 9 Meters Pipeline NM-136 Mechanism of Action: • GIP mAb decreases nutrient uptake & fat storage and potentially effective in metabolic and obesity-related disorders, where this is a key problem • GIP mAb also potentially decreases intest
Slide 7: NM-136 Pre-Clinical Data Showed Key Improvements
NM-136 Pre-Clinical Data Showed Key Improvements • In this study done in mice, NM-136 (30 mg/kg) attenuated the insulin response to oral glucose by 2/3 and eliminated the insulin response to co-administered glucose. • The effect at 60 mg/kg weekly on weight gain decreased by 46.5% and was equivalent
Slide 8: Prader-Willi Syndrome Overview
Prader-Willi Syndrome Overview Prader-Willi syndrome is characterized by: • Weight gain caused by hyperphagia: Chronic feeling of insatiable hunger causing morbid obesity • Hyperphagia starts at very young age and usually lasts until death • Intellectual/emotional disabilities and psychiatric disord
Slide 9: NM-136 Development Plan & Timeline
Mid 2021 NM-136 acquired by 9 Meters IND-enabling and CMC optimization underway by Lobesity Late 2021/Full Year 2022 Complete IND-enabling program Pre-IND meeting IND preparation/filing mAb production/scale-up 2023 Bioanalytical Start Phase 1/Human PK NM-136 Development Plan & Timeline 9
Slide 10: Thank You
Thank You John Temperato President & CEO jtemperato@9meters.com Edward Sitar Chief Financial Officer esitar@9meters.com 8480 Honeycutt Road, Suite 120 Raleigh, NC 27615 Telephone: 1-919-275-1933 info@9meters.com www.9meters.com Twitter LinkedIn
9 Meters Biopharma — Merger or Acquisition (July 2021) on 6ix